Clinical Trial Update: Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2) [Phase 2]

View source ↗

Summary

Phase 2 study completed evaluating the efficacy and safety of ASF-1096 Cream 0.5% in discoid lupus erythematosus lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Discoid Lupus Erythematosus

Drugs mentioned

• ASF-1096 Cream 0.5%

Snippet

Sponsor: Astion Pharma A/S | Conditions: Discoid Lupus Erythematosus | Phase 2 | Status: COMPLETED